Intellia Therapeutics Enters Material Definitive Agreement
Ticker: NTLA · Form: 8-K · Filed: Feb 21, 2025 · CIK: 1652130
Sentiment: neutral
Topics: material-agreement, financial-obligation
TL;DR
Intellia inked a new deal, expect financial moves.
AI Summary
Intellia Therapeutics, Inc. entered into a material definitive agreement on February 18, 2025. This agreement creates a direct financial obligation or an obligation under an off-balance sheet arrangement for the registrant. Further details regarding the nature and terms of this agreement are not provided in this filing.
Why It Matters
This filing indicates a significant new financial commitment or obligation for Intellia Therapeutics, which could impact its financial standing and future operations.
Risk Assessment
Risk Level: medium — The filing indicates a material definitive agreement and financial obligation, but lacks specific details, creating uncertainty.
Key Players & Entities
- Intellia Therapeutics, Inc. (company) — Registrant
- February 18, 2025 (date) — Date of Earliest Event Reported
- 001-37766 (other) — Commission File Number
- 36-4785571 (other) — IRS Employer Identification No.
- 40 Erie Street, Suite 130 Cambridge, Massachusetts 02139 (address) — Principal Executive Offices
FAQ
What type of material definitive agreement did Intellia Therapeutics enter into?
The filing states that Intellia Therapeutics, Inc. entered into a material definitive agreement, but does not specify the type of agreement.
What is the nature of the financial obligation created by this agreement?
The filing indicates the agreement creates a direct financial obligation or an obligation under an off-balance sheet arrangement, but does not provide specific details about the obligation itself.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on February 18, 2025.
What is Intellia Therapeutics' principal executive office address?
Intellia Therapeutics' principal executive office is located at 40 Erie Street, Suite 130, Cambridge, Massachusetts 02139.
What is Intellia Therapeutics' Commission File Number?
Intellia Therapeutics' Commission File Number is 001-37766.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on February 21, 2025 regarding Intellia Therapeutics, Inc. (NTLA).